Nuvectis NXP200 achieves 40% ORR in high-grade glioma Phase 1b
Nuvectis Pharma has reported expanded Phase 1b data for NXP200, its second-generation BRAF inhibitor, in patients with recurrent or progressive BRAF V600-mutated gliomas. The results, presented as an oral session at the European Society for Medical Oncology Congress in Madrid on 26 October, show response rates and durability that the company says position NXP200 as a potential best-in-class agent in the indication.
Across 27 efficacy-evaluable patients treated with NXP200 monotherapy, the objective response rate reached 40.0% (8 of 20 patients) in the high-grade glioma cohort and 42.9% (3 of 7 patients) in the low-grade cohort, assessed by RANO 2.0 criteria. Notably, both cohorts included confirmed complete responses: three in the high-grade group and one in the low-grade group. Deep responses, defined as greater than 80% tumour burden reduction, were recorded in 87.5% of high-grade responders and 66.7% of low-grade responders. The overall disease control rate across all 27 patients was 85.2%.
Durability and safety
Survival data add further context to the efficacy picture. In the high-grade cohort, median duration of response was 6.97 months and median overall survival was 17.15 months; in the low-grade cohort, neither endpoint had been reached at the May 2026 data cut-off. Twelve-month survival stood at 95% and 100% in the high-grade and low-grade groups respectively. Among 28 safety-evaluable patients, 14.3% experienced a Grade 3 or higher treatment-related adverse event, and no treatment-related adverse event led to discontinuation or death.
Particularly encouraging for the programme's competitive positioning is the signal in previously BRAF-inhibitor-treated patients: two of three such patients achieved a partial response and one had stable disease. First-generation BRAF inhibitors are associated with paradoxical pathway activation in gliomas, which can limit their utility; NXP200's paradox-breaking mechanism is designed to circumvent that effect.
Ron Bentsur, chairman and chief executive of Nuvectis, said the depth of observed responses, including complete responses and tumours with more than 80% burden reduction, together with "the ability to induce responses in patients previously treated with a BRAF inhibitor while maintaining a manageable safety profile," make the emerging profile of NXP200 encouraging.
Market context and regulatory path
The BRAF V600 mutation is present in roughly 5 to 10% of glioma cases, making it a genomically defined but still substantial target population. The approved standard-of-care option, dabrafenib plus trametinib (a BRAF-MEK combination from Novartis), carries a paediatric label for low-grade glioma in several markets. NXP200's capacity to generate responses in patients who have already progressed on BRAF inhibition would, if confirmed in later-stage studies, represent a clinically meaningful differentiator.
Nuvectis in-licensed exclusive worldwide rights outside Greater China from Haisco Pharmaceutical Group in June 2026; the Phase 1b study itself is being conducted by Haisco in China. In September 2026, China's Centre for Drug Evaluation granted NXP200 Breakthrough Therapy Designation for recurrent or progressive high-grade glioma, and the programme was selected as a pilot under China's Starlight paediatric anti-tumour drug scheme. Nuvectis said it remains on track to file a US Investigational New Drug application before the end of 2026, which would be the next major milestone for investors tracking the programme's path toward a US pivotal study.